Sionna Therapeutics was formed in 2019, leveraging more than a decade of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. Our programs targeting the NBD1, ICL4, and TMD1 regions of CFTR are complementary, and together they have the potential to achieve best in class efficacy by normalizing CFTR function.

In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Sionna Therapeutics wants to change that. Our values drive us to redefine what is possible for patients.

Core Values

Excellence together to redefine what is possible for patients

Leadership Team

Board of Directors

Clinical Advisors

Scientific Advisors